SCHEMBL9993508

SCHEMBL9993508

CCOC(=O)NC1CC2(CCN(C(=O)O)CC2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
ROCK2 O75116 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
ATM Q13315 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
DRD2 P14416 1/20 0.34
TSHR P16473 1/20 0.33
ENPP2 Q13822 1/20 0.33
ATXN2 Q99700 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9994510 0.83 EPHX1 (0.43) HSD11B1LMNATHRBKMT2AMEN1
SCHEMBL3720045 0.76 HSD11B1 (0.37) HSD11B1L3MBTL1LMNATHRBATM
SCHEMBL20399556 0.75 CYP2C19 (0.33) KMT2AMEN1TSHRPOLBALDH1A1
SCHEMBL27147272 0.75 HSD11B1 (0.61) HSD11B1L3MBTL1THRBATMKMT2A
SCHEMBL30807383 0.75 HSD11B1 (0.61) HSD11B1L3MBTL1THRBATMKMT2A
SCHEMBL3937465 0.71 KMT2A (0.46) HSD11B1L3MBTL1LMNATHRBATM
SCHEMBL3720049 0.71 HSD11B1 (0.36) HSD11B1L3MBTL1LMNATHRBATM
SCHEMBL27858120 0.71 NFKB1 (0.42) HSD11B1LMNAKMT2AMEN1NFKB1
SCHEMBL18319191 0.70 ALDH1A1 (0.35) L3MBTL1LMNATHRBATMTSHR
SCHEMBL20414854 0.69 GAA (0.47) L3MBTL1THRBATMKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889702-B2 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-11-18 US disclosed
EP-2393809-B1 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-04-30 EP disclosed
US-20110319381-A1 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319381-A1 DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PRMT9, IDH3B, DHFR HSD11B1 726/4885ROCK2 3449/4885L3MBTL1 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.